BFRINasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BFRIW

Biofrontera Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.81−0.02 (-1.94%)

Close on Oct 19, 2026

Market cap: $10.41M
P/E (TTM): –
Dividend yield: –

Biofrontera Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	42	37	34	29	24	19
Research & Development	3.72	2.09	0.08	–	–	–
Selling, General & Admin	38	34	39	35	37	18
General & Administrative	23	16	18	–	–	–
Advertising Expenses	–	–	0.20	0.10	0.50	0.30
Operating Expenses	53	55	57	47	49	28
Total Costs & Expenses	53	55	57	–	–	–
Operating Income	-11	-17	-23	-19	-25	-9.61
Interest Expense	–	–	0.22	0.01	0.34	2.87
Interest & Investment Income	–	0.07	0.13	0.01	0.02	0.03
Income from Equity Investments	0.00	-0.01	-7.42	1.75	–	–
Other Non-Operating Income	0.84	-0.53	2.56	18	-12	-1.32
Merger & Restructuring Charges	–	–	–	0	0.75	1.13
Gain (Loss) on Investments	0.00	-0.01	-7.42	1.75	–	–
Legal Settlements	–	–	7.39	–	–	–
Pretax Income	-11	-18	-20	-0.61	-38	-11
Income Tax Expense	0.03	0.02	0.01	0.03	0.06	0.06
Net Income	-11	-18	-20	-0.64	-38	-11
Net Income to Common	–	–	–	–	-38	-11
EPS (Basic)(per share)	-1.04	-3.22	-13.02	-0.61	-85.60	-9,589.60
EPS (Diluted)(per share)	-1.04	-3.22	-13.02	-0.61	-85.60	-9,589.60
Shares Outstanding (Basic, Weighted)(shares)	10	5.52	1.55	1.06	0.44	1.15
Shares Outstanding (Diluted, Weighted)(shares)	10	5.52	1.55	1.06	440	1.15
EBITDA	-11	-17	-22	–	–	–
Net Interest Income	–	–	-0.47	-0.20	-0.34	-2.87

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -14.2%
Net margin: -13.8%
Return on equity, FY2025: -141.3%

Financial strength

Current ratio: 1.18
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 44.2%

Valuation

P/E ratio: –
Price to sales: 0.23
Price to book: 1.75
Dividend yield: –